ELI LILLY AND COMPANY Accrued Income Taxes, Current
ELI LILLY AND COMPANY (LLY) had Accrued Income Taxes, Current of $153.50 million as of 2014-09-30, per its 10-Q filed 2014-10-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2014-10-29
- 2014-09-30: Accrued Income Taxes, Current $153.50M.
- 2014-06-30: Accrued Income Taxes, Current $168.60M.
- 2014-03-31: Accrued Income Taxes, Current $102.50M.
- 2013-12-31: Accrued Income Taxes, Current $254.40M.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2014-09-30 | $153.50M 10-Q · filed 2014-10-29 |
| 2014-06-30 | $168.60M 10-Q · filed 2014-07-28 |
| 2014-03-31 | $102.50M 10-Q · filed 2014-04-28 |
| 2013-12-31 | $254.40M 10-Q · filed 2014-10-29 |
| 2013-09-30 | $37.50M 10-Q · filed 2013-10-30 |
| 2013-06-30 | $37.30M 10-Q · filed 2013-07-26 |
| 2013-03-31 | $352.70M 10-Q · filed 2013-04-26 |
| 2012-12-31 | $143.50M 10-Q · filed 2013-10-30 |
| 2012-09-30 | $338.20M 10-Q · filed 2012-10-26 |
| 2012-06-30 | $33.50M 10-Q · filed 2012-07-27 |
| 2012-03-31 | $388.80M 10-Q · filed 2012-04-30 |
| 2011-12-31 | $261.60M 10-Q · filed 2012-10-26 |
| 2009-12-31 | $346.70M 10-K · filed 2010-02-22 |
| 2008-12-31 | $229.20M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |